Liver Cirrhosis:
Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Tokyo
Springer Japan
2001
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the informative talks by those guests from abroad, the lecture by Dr. J. Fujimoto was very impressive. He revealed that gene therapy using hepatocyte growth factor (HGF) could inhibit progression to liver cirrhosis in rats repeatedly injected with dimethylnitrosamine (DMN). Dr. Fujimoto has already pub lished his finding that administration of HGF reduced hepatocarcinogenesis in rats |
| Beschreibung: | 1 Online-Ressource (XII, 125 p) |
| ISBN: | 9784431683438 |
| DOI: | 10.1007/978-4-431-68343-8 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046144303 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 9784431683438 |9 978-4-431-68343-8 | ||
| 024 | 7 | |a 10.1007/978-4-431-68343-8 |2 doi | |
| 035 | |a (ZDB-2-SME)978-4-431-68343-8 | ||
| 035 | |a (OCoLC)1119009635 | ||
| 035 | |a (DE-599)BVBBV046144303 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.36 |2 23 | |
| 084 | |a YC 5605 |0 (DE-625)153237:12911 |2 rvk | ||
| 245 | 1 | 0 | |a Liver Cirrhosis |c edited by Kiwamu Okita |
| 264 | 1 | |a Tokyo |b Springer Japan |c 2001 | |
| 300 | |a 1 Online-Ressource (XII, 125 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the informative talks by those guests from abroad, the lecture by Dr. J. Fujimoto was very impressive. He revealed that gene therapy using hepatocyte growth factor (HGF) could inhibit progression to liver cirrhosis in rats repeatedly injected with dimethylnitrosamine (DMN). Dr. Fujimoto has already pub lished his finding that administration of HGF reduced hepatocarcinogenesis in rats | ||
| 650 | 4 | |a Hepatology | |
| 650 | 4 | |a Clinical medicine | |
| 650 | 0 | 7 | |a Leberzellkrebs |0 (DE-588)4133881-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Leberzirrhose |0 (DE-588)4034948-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Leberfibrose |0 (DE-588)4167063-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1999 |z Yamaguchi |2 gnd-content | |
| 689 | 0 | 0 | |a Leberzirrhose |0 (DE-588)4034948-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Leberfibrose |0 (DE-588)4167063-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Leberzellkrebs |0 (DE-588)4133881-9 |D s |
| 689 | 2 | |5 DE-604 | |
| 700 | 1 | |a Okita, Kiwamu |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9784431683452 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9784431683445 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9784431702948 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-4-431-68343-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524488 | ||
| 966 | e | |u https://doi.org/10.1007/978-4-431-68343-8 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180479510839296 |
|---|---|
| any_adam_object | |
| author2 | Okita, Kiwamu |
| author2_role | edt |
| author2_variant | k o ko |
| author_facet | Okita, Kiwamu |
| building | Verbundindex |
| bvnumber | BV046144303 |
| classification_rvk | YC 5605 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-4-431-68343-8 (OCoLC)1119009635 (DE-599)BVBBV046144303 |
| dewey-full | 616.36 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.36 |
| dewey-search | 616.36 |
| dewey-sort | 3616.36 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-4-431-68343-8 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03517nmm a2200541zc 4500</leader><controlfield tag="001">BV046144303</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9784431683438</subfield><subfield code="9">978-4-431-68343-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-4-431-68343-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-4-431-68343-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119009635</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144303</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.36</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 5605</subfield><subfield code="0">(DE-625)153237:12911</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Liver Cirrhosis</subfield><subfield code="c">edited by Kiwamu Okita</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Tokyo</subfield><subfield code="b">Springer Japan</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 125 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the informative talks by those guests from abroad, the lecture by Dr. J. Fujimoto was very impressive. He revealed that gene therapy using hepatocyte growth factor (HGF) could inhibit progression to liver cirrhosis in rats repeatedly injected with dimethylnitrosamine (DMN). Dr. Fujimoto has already pub lished his finding that administration of HGF reduced hepatocarcinogenesis in rats</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical medicine</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Leberzellkrebs</subfield><subfield code="0">(DE-588)4133881-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Leberzirrhose</subfield><subfield code="0">(DE-588)4034948-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Leberfibrose</subfield><subfield code="0">(DE-588)4167063-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1999</subfield><subfield code="z">Yamaguchi</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Leberzirrhose</subfield><subfield code="0">(DE-588)4034948-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Leberfibrose</subfield><subfield code="0">(DE-588)4167063-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Leberzellkrebs</subfield><subfield code="0">(DE-588)4133881-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okita, Kiwamu</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9784431683452</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9784431683445</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9784431702948</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-4-431-68343-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524488</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-4-431-68343-8</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1999 Yamaguchi gnd-content |
| genre_facet | Konferenzschrift 1999 Yamaguchi |
| id | DE-604.BV046144303 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:25Z |
| institution | BVB |
| isbn | 9784431683438 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524488 |
| oclc_num | 1119009635 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 125 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Springer Japan |
| record_format | marc |
| spelling | Liver Cirrhosis edited by Kiwamu Okita Tokyo Springer Japan 2001 1 Online-Ressource (XII, 125 p) txt rdacontent c rdamedia cr rdacarrier Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the informative talks by those guests from abroad, the lecture by Dr. J. Fujimoto was very impressive. He revealed that gene therapy using hepatocyte growth factor (HGF) could inhibit progression to liver cirrhosis in rats repeatedly injected with dimethylnitrosamine (DMN). Dr. Fujimoto has already pub lished his finding that administration of HGF reduced hepatocarcinogenesis in rats Hepatology Clinical medicine Leberzellkrebs (DE-588)4133881-9 gnd rswk-swf Leberzirrhose (DE-588)4034948-2 gnd rswk-swf Leberfibrose (DE-588)4167063-2 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1999 Yamaguchi gnd-content Leberzirrhose (DE-588)4034948-2 s DE-604 Leberfibrose (DE-588)4167063-2 s Leberzellkrebs (DE-588)4133881-9 s Okita, Kiwamu edt Erscheint auch als Druck-Ausgabe 9784431683452 Erscheint auch als Druck-Ausgabe 9784431683445 Erscheint auch als Druck-Ausgabe 9784431702948 https://doi.org/10.1007/978-4-431-68343-8 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Liver Cirrhosis Hepatology Clinical medicine Leberzellkrebs (DE-588)4133881-9 gnd Leberzirrhose (DE-588)4034948-2 gnd Leberfibrose (DE-588)4167063-2 gnd |
| subject_GND | (DE-588)4133881-9 (DE-588)4034948-2 (DE-588)4167063-2 (DE-588)1071861417 |
| title | Liver Cirrhosis |
| title_auth | Liver Cirrhosis |
| title_exact_search | Liver Cirrhosis |
| title_full | Liver Cirrhosis edited by Kiwamu Okita |
| title_fullStr | Liver Cirrhosis edited by Kiwamu Okita |
| title_full_unstemmed | Liver Cirrhosis edited by Kiwamu Okita |
| title_short | Liver Cirrhosis |
| title_sort | liver cirrhosis |
| topic | Hepatology Clinical medicine Leberzellkrebs (DE-588)4133881-9 gnd Leberzirrhose (DE-588)4034948-2 gnd Leberfibrose (DE-588)4167063-2 gnd |
| topic_facet | Hepatology Clinical medicine Leberzellkrebs Leberzirrhose Leberfibrose Konferenzschrift 1999 Yamaguchi |
| url | https://doi.org/10.1007/978-4-431-68343-8 |
| work_keys_str_mv | AT okitakiwamu livercirrhosis |